X-Linked Spondyloepiphyseal Dysplasia Tarda (SEDT) — Comprehensive Disease Report

MONDO: MONDO:0010737 · OMIM (phenotype): 313400 · OMIM (gene): 300202 · Gene: TRAPPC2 (SEDL), Xp22.2 · Category: Mendelian, X-linked recessive

Evidence base: This report is compiled from aggregated disease-level resources (OMIM, Orphanet) and primary human genetic/clinical literature (case series, pedigrees, molecular studies) plus in vitro / cell-biology mechanistic studies. There are no population EHR datasets or omics data files for this ultra-rare disorder; findings derive from individual pedigrees and mechanistic experiments. Evidence type is indicated per claim: (human clinical), (in vitro), (human tissue), (yeast/comparative).

Summary

X-linked spondyloepiphyseal dysplasia tarda (SEDT) is a rare (~2 per 1,000,000), non-lethal, X-linked recessive osteochondrodysplasia caused by loss-of-function mutations in TRAPPC2 (SEDL) at Xp22.2, which encodes sedlin, a small 140-amino-acid protein. Sedlin is the Trs20 adaptor subunit of the conserved TRAPP tethering complex and a regulator of the secretory pathway. The central mechanistic insight is that SEDT is a disease of procollagen export from the endoplasmic reticulum in growth-plate chondrocytes: sedlin binds and promotes efficient cycling of the Sar1 GTPase, allowing nascent COPII carriers to enlarge into "megacarriers" capable of exporting bulky procollagen prefibrils. Loss of sedlin blocks this export, producing a secretory bottleneck (dilated rough ER) and defective chondrogenesis.

Clinically, affected hemizygous males are normal at birth and present in late childhood/adolescence (~5–14 y) with disproportionate short-trunk short stature, barrel chest, pathognomonic hump-shaped platyspondyly, and premature secondary osteoarthritis of the spine and hips. Because the defect is confined to the skeleton, metabolic laboratory values are normal (a key diagnostic discriminator from mucopolysaccharidoses) and life expectancy is normal. Female carriers are usually asymptomatic. Diagnosis rests on characteristic radiographs plus an X-linked pedigree, confirmed by TRAPPC2 sequencing.

There is no disease-modifying therapy. Management is symptomatic and orthopedic — NSAIDs, physiotherapy, joint protection, and total hip arthroplasty for end-stage hip osteoarthritis (which yields large functional gains). Prevention is reproductive/genetic: counseling, carrier testing, prenatal diagnosis, and PGT-M once the familial variant is known. This report presents eight confirmed findings, a stepwise causal model, the supporting evidence base, and the full 15-section disease-knowledge-base template.

Key Findings

Finding 1 — SEDT is caused by loss-of-function mutations in TRAPPC2/SEDL

SEDT is an X-linked recessive osteochondrodysplasia caused by mutations in TRAPPC2 (SEDL) that almost invariably eliminate functional sedlin (loss of function). Independent pedigrees across Japanese, Chinese, European, and Australian families show cosegregation under X-linked recessive inheritance, spanning nonsense (c.61G>T/p.E21 PMID: 24841781; S110X PMID: 12446987), frameshift (2-bp exon-5 deletion PMID: 11760838), splice-site (IVS2-2A>C → exon 3 skipping PMID: 16120574; recurrent c.93+5G>A PMID: 11326333; c.93+5G>C PMID: 23876379), and intragenic deletions removing the start codon (PMID: 11252002). The Japanese family study established the mechanism directly: "The nature of the mutation predicted that the SEDL protein (Sedlin) was not produced in the proband, indicating that loss of Sedlin caused SEDT" (PMID: 11252002). A splice study confirmed the same logic — because the start site is on exon 3 — "the splicing defect causes affected individuals failure to produce sedlin, which elucidates the causative role of SEDL gene" (PMID: 16120574). Inheritance and clinical hallmark were summarized in a five-generation Chinese pedigree: "Spondyloepiphyseal dysplasia tarda (SEDT) is an X-linked recessive osteochondrodysplasia characterized by disproportionately short stature and degenerative joint disease" (PMID: 24841781). Ontology:* HGNC:23068 (TRAPPC2); MONDO:0010737.

Finding 2 — Sedlin promotes ER export of procollagen by regulating the Sar1 GTPase cycle

The landmark study of Venditti et al. (2012) defined sedlin's molecular function and linked it to tissue pathology: the cargo receptor TANGO1 recruits sedlin, which is required for ER export of procollagen (PC). "Sedlin bound and promoted efficient cycling of Sar1" — the GTPase that controls COPII budding (PMID: 23019651). By promoting Sar1 turnover, sedlin lets COPII carriers grow into megacarriers large enough for bulky procollagen prefibrils. Critically, "this joint action of TANGO1 and Sedlin sustained the ER export of PC, and its derangement may explain the defective chondrogenesis underlying SEDT" (PMID: 23019651). Biochemical studies show disease missense mutants S73L, F83S, and V130D misfold and are proteasomally degraded (rescued by MG132), while D47Y folds normally but has altered Bet3 binding — two routes to loss of function (PMID: 19650763). The same study localized sedlin to "proliferating and hypertrophic chondrocytes" (PMID: 19650763), the growth-plate cells where the defect manifests. Ontology: GO:0006888 (ER-to-Golgi transport); GO:0090110 (COPII cargo loading); CL:0000138 (chondrocyte).

Finding 3 — Clinical hallmark: short-trunk short stature, hump-shaped platyspondyly, premature osteoarthritis

Affected hemizygous males present in late childhood/adolescence with disproportionately short trunk/stature and a barrel-chest deformity: "presents with disproportionate short stature and 'barrel-chest' deformity in affected (hemizygous) adolescent boys" (PMID: 11760838). The radiographic hallmark is platyspondyly with a hump-shaped (posterior/central) vertebral mound, end-plate sclerosis, disc-space narrowing, short thick femoral necks, narrow hips, and pelvic osteosclerosis: "His radiographs showed platyspondyly with posterior humping, narrow hip-joint surfaces, and pelvic osteosclerosis" (PMID: 32471379), and "Radiographically the disorder is characterized by a typical hump-shaped deformity of the vertebral bodies" (PMID: 15221797). Early degenerative joint disease of spine and hips is near-universal; carriers are usually asymptomatic (PMID: 11760838). Ontology (HPO): HP:0000926 (Platyspondyly); HP:0004322 (Short stature); HP:0002758 (Osteoarthritis); HP:0002656 (Epiphyseal dysplasia).

Finding 4 — Gene structure, epidemiology, and X-inactivation escape

SEDL/TRAPPC2 maps to Xp22.2, is a 2.8-kb transcript expressed broadly including fetal cartilage, and encodes sedlin, 140 aa: "SEDL encodes a 140 amino acid protein with a putative role in endoplasmic reticulum (ER)-to-Golgi vesicular transport" (PMID: 10431248). Prevalence: "an X-linked recessive osteochondrodysplasia that occurs in approximately two of every one million people" (PMID: 10431248). The gene escapes X-inactivation — "RT-PCR experiments using mouse/human cell hybrids revealed that the SEDL gene escapes X inactivation" (PMID: 11326333) — has a transcribed retropseudogene on chr19, and conserved orthologues from yeast (p20/Trs20) to mammals. The recurrent c.93+5G>A allele appears in multiple unrelated families (PMID: 11326333, PMID: 26252088).

Finding 5 — Ultrastructural pathology confirms a secretory-pathway defect

Articular cartilage from an adult SEDT patient carrying c.93+5G>A contained chondrocytes with abundant Golgi and dilated rough ER: "Articular cartilage from an adult who had SEDL and carried this mutation contained chondrocytes with abundant Golgi complexes and dilated rough endoplasmic reticulum (ER)" (PMID: 11326333). The distended ER is the morphological signature of a secretory bottleneck (procollagen retention). The authors concluded: "These data suggest that SEDL mutations may perturb an intracellular pathway that is important for cartilage homeostasis" (PMID: 11326333). Ontology: GO:0005783 (ER); GO:0005794 (Golgi).

Finding 6 — Sedlin (Trs20) is an essential TRAPP adaptor with Rab-GEF activity

TRAPP is a conserved modular "transport protein particle" complex acting as a Ypt/Rab GTPase GEF: "TRAPP attracted attention when it was shown to act as a Ypt/Rab GTPase nucleotide exchanger, GEF" (PMID: 27066478). Sedlin is the adaptor for higher-order assembly: "Another small subunit, Trs20/Sedlin, is an adaptor required for the association of core TRAPP with larger subunits to form TRAPP II and TRAPP III" (PMID: 27066478). TRAPP regulates both secretion and autophagy, so sedlin loss could in principle affect both; the secretory (procollagen) branch is the demonstrated driver of SEDT. Ontology: GO:0030008 (TRAPP complex); GO:0006914 (autophagy — inferred).

Finding 7 — Management is orthopedic; total hip arthroplasty is effective for end-stage hip OA

No curative therapy exists; care is supportive/orthopedic. Because the dysplasia "usually leads to premature secondary osteoarthritis often requiring hip arthroplasty" (PMID: 10431248), THA is the mainstay for end-stage disease. In a series of SED patients with Tönnis grade 3 hip OA, THA improved mean Harris hip score from 35.55 preoperatively to 89.56, with reduced pain (VAS) and improved SF-12, and low short-term complications (PMID: 33550353). Registry data show THA durability in pediatric hip diseases is comparable to primary OA after adjustment (PMID: 23043269). Life expectancy is normal: SEDT features "disproportionate short stature with short neck and trunk, barrel chest and absence of systemic complications" (PMID: 10431248). Ontology (NCIT): Total Hip Arthroplasty; NSAID Therapy; Physical Therapy.

Finding 8 — Diagnosis rests on radiographs plus normal labs and X-linked pedigree, confirmed by sequencing

Clinical diagnosis is challenging: "Clinical diagnosis can be challenging due to the late-onset of the disease and lack of systemic metabolic abnomalites [sic]. Genetic diagnosis is critical in both early diagnosis and management of the disease" (PMID: 32471379). The diagnostic triad is platyspondyly with posterior humping, narrow hip-joint surfaces, and pelvic osteosclerosis (PMID: 32471379). Definitive diagnosis is by TRAPPC2 sequencing (ACMG-classified). Once the familial variant is known, "Molecular testing of SEDL enables carrier detection and definitive diagnosis before clinical or radiographic expression of SEDT" (PMID: 11760838). Key differential: SED tarda with progressive arthropathy (PPAC, WISP3/CCN6; PMID: 10870664), SED congenita (COL2A1), multiple epiphyseal dysplasia, and mucopolysaccharidoses (abnormal urinary GAGs — absent in SEDT).

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. A loss-of-function TRAPPC2 mutation in a hemizygous male leads to absent or misfolded sedlin (NMD of null alleles; proteasomal degradation of destabilizing missense mutants). (demonstrated — PMID: 11252002, PMID: 19650763)
2. Loss of sedlin results in failure of its role as the Trs20 adaptor for TRAPP II/III assembly and loss of function at ER exit sites. (demonstrated in vitro — PMID: 27066478)
3. In chondrocytes, TANGO1 normally recruits sedlin, which binds and promotes efficient cycling of Sar1; without sedlin, Sar1 cycling is impaired and COPII carriers cannot enlarge into megacarriers. (demonstrated in vitro — PMID: 23019651)
4. Impaired megacarrier growth leads to defective ER export of procollagen (too large for standard COPII vesicles). (demonstrated in vitro — PMID: 23019651)
5. Procollagen accumulates in a dilated rough ER (with expanded Golgi) in patient chondrocytes — a secretory bottleneck. (demonstrated, human tissue — PMID: 11326333)
6. Reduced secretion of cartilage collagen matrix results in defective chondrogenesis/endochondral ossification at vertebral and epiphyseal growth plates (sedlin is expressed in proliferating/hypertrophic chondrocytes). (inferred from mechanism + expression — PMID: 19650763, PMID: 23019651)
7. Growth-plate dysfunction leads to the skeletal phenotype — platyspondyly, epiphyseal dysplasia, short trunk — visible only after years of growth (hence "tarda"). (human clinical — PMID: 10431248, PMID: 15221797)
8. Abnormal joint/vertebral architecture results in altered biomechanics and premature secondary osteoarthritis of spine and hips → chronic pain and disability, treated by arthroplasty. (human clinical — PMID: 10431248, PMID: 33550353)

Branch point: TRAPP also functions in autophagy and general ER–Golgi trafficking (PMID: 27066478); in principle sedlin loss could perturb these broadly, yet the phenotype is skeleton-restricted — inferred to reflect the exceptionally high demand for large procollagen cargo export in chondrocytes rather than a global trafficking collapse.

TRAPPC2 (Xp22.2) loss-of-function mutation
        │  absent / misfolded sedlin (Trs20)
        ▼
Defective TRAPP assembly + impaired Sar1 GTPase cycling
        ▼
COPII "megacarriers" fail to form ──► procollagen cannot exit ER
        ▼
Dilated rough ER + expanded Golgi in growth-plate chondrocytes (CL:0000138)
        ▼
Defective chondrogenesis / abnormal endochondral ossification
        ├──► Platyspondyly (hump-shaped vertebrae) ──► short-trunk stature, barrel chest
        └──► Epiphyseal dysplasia (hips) ──► premature secondary osteoarthritis
                                                     ▼
                                        Total hip arthroplasty (symptomatic Tx)

Upstream vs downstream: mutation and sedlin loss are upstream; the Sar1/COPII/procollagen-export defect is the proximal molecular mechanism; ER distension and defective chondrogenesis are the cellular midpoints; the skeletal phenotype with secondary OA is the downstream endpoint. Cell type: growth-plate chondrocyte (CL:0000138). Anatomy: vertebral column (UBERON:0001130), epiphyseal plate (UBERON:0006255/0002515), hip joint (UBERON:0001464).

Full Disease-Knowledge-Base Template (Sections 1–15)

1. Disease Information

Overview. SEDT is a rare, non-lethal X-linked recessive osteochondrodysplasia affecting primarily the vertebrae (spondylo-) and epiphyses. It is "tarda" (late) because affected boys are normal at birth, with skeletal signs emerging typically between ~5 and 14 years. Cardinal features are disproportionate short-trunk short stature, a barrel/short chest, and characteristic platyspondyly with a hump-shaped mound on the central/posterior vertebral bodies, leading to premature secondary osteoarthritis of spine and large joints (especially hips) without systemic metabolic complications (PMID: 10431248, PMID: 15221797) (human clinical).

"Spondyloepiphyseal dysplasia tarda (SEDL; MIM 313400) is an X-linked recessive osteochondrodysplasia that occurs in approximately two of every one million people." (PMID: 10431248)

Key identifiers. - OMIM phenotype: 313400 (Spondyloepiphyseal dysplasia tarda, X-linked) - OMIM gene: 300202 (TRAPPC2 / SEDL) - Orphanet: ORPHA:93284 (X-linked spondyloepiphyseal dysplasia tarda) - ICD-10: Q77.7 (Spondyloepiphyseal dysplasia) - ICD-11: ~LD24.1 (spondyloepiphyseal dysplasias) — verify exact code - MeSH: Osteochondrodysplasias (D010009); no unique dedicated descriptor - MONDO: MONDO:0010737 - Gene: TRAPPC2 (HGNC:23068; formerly SEDL); NCBI Gene ID 6399; cytoband Xp22.2; protein sedlin

Synonyms. SEDT; SED tarda; SEDL; X-linked spondyloepiphyseal dysplasia; spondyloepiphyseal dysplasia tarda, X-linked; sedlin deficiency. (Autosomal "SED tarda with progressive arthropathy" is genetically distinct — see §10.)

Evidence source: aggregated disease-level resources (OMIM, Orphanet) + individual pedigrees; not EHR/population data.

2. Etiology

Primary cause — genetic (monogenic). SEDT is caused by loss-of-function mutations in TRAPPC2/SEDL on Xp22.2 encoding sedlin (PMID: 10431248, PMID: 11252002) (human clinical). It is not infectious, environmental, or multifactorial.

Genetic risk factors. Hemizygous pathogenic TRAPPC2 variants in males essentially fully determine disease. Male sex and an affected/carrier mother are the defining risk determinants (X-linked recessive). No susceptibility loci or modifier genes are established.

Protective factors. In heterozygous females, a normal X allele plus random X-inactivation renders most carriers asymptomatic (dosage protection). No protective modifier alleles described.

Environmental risk/protective factors & gene–environment interactions. None recognized — as expected for a fully penetrant Mendelian trafficking defect. Phenotypic variability exists (severe child vs mild adult, PMID: 11491516) but no molecular modifier has been mapped.

3. Phenotypes

All phenotypes are physical manifestations / clinical signs of a skeletal dysplasia; there are no characteristic laboratory abnormalities (normal blood/urine chemistry, normal mucopolysaccharides), a key diagnostic discriminator (PMID: 32471379). Onset is childhood (~5–14 y); course is chronic and slowly progressive; penetrance in hemizygous males is essentially complete with variable expressivity.

Quality-of-life impact. Morbidity is musculoskeletal: chronic back and hip pain, reduced mobility/stamina, and functional limitation from early OA dominate. Instruments used in SED hip-OA literature include Harris Hip Score, WOMAC, VAS, SF-12 (PMID: 33550353). No cognitive, cardiac, respiratory-failure, or visceral involvement.

4. Genetic / Molecular Information

Causal gene. TRAPPC2 (SEDL), Xp22.2, HGNC:23068, NCBI Gene 6399, OMIM 300202; encodes sedlin (140 aa), a 2.8-kb transcript expressed broadly including fetal cartilage (PMID: 10431248). A near-identical paralog TRAPPC2B and a transcribed retropseudogene on chr19 exist — relevant to assay design (PMID: 11326333).

Pathogenic variant spectrum (all germline; LoF). - Frameshift/indels: dinucleotide deletions with premature stops (PMID: 10431248); 2-bp exon-5 deletion (PMID: 11760838); additional small indels (PMID: 15221797). - Nonsense: c.61G>T/p.E21 (PMID: 24841781); S110X (PMID: 12446987). - Splice-site: recurrent c.93+5G>A (IVS3+5G>A) hot spot causing exon-3 skipping (PMID: 11326333, PMID: 26252088); c.93+5G>C (PMID: 23876379); IVS2-2A>C (PMID: 16120574). - Missense: D47Y, S73L, F83S, V130D (PMID: 19650763); c.218C>T (PMID: 18247296) — rarer; mostly destabilize the protein. - Gross deletions:* intragenic deletion removing the start codon/exon 3 (PMID: 11252002); whole-exon deletions (PMID: 15221797).

Functional consequence: predominantly loss of function / absence of sedlin (NMD, no protein, or misfolded protein degraded by the proteasome) (PMID: 11252002, PMID: 19650763). No gain-of-function or dominant-negative mechanism. Missense S73L/F83S/V130D misfold and are proteasomally degraded (rescued by MG132); D47Y folds normally but shows altered Bet3 binding (PMID: 19650763) (in vitro).

Variant classification. Reported variants are Pathogenic/Likely pathogenic under ACMG criteria (null variants in a LoF gene; cosegregation; absent from controls/gnomAD) (PMID: 32471379). Allele frequency: disease alleles absent/ultra-rare in gnomAD/1000 Genomes; absent from ≥100 control chromosomes in multiple studies (PMID: 11326333, PMID: 23876379).

Somatic vs germline: entirely germline. Modifiers/epigenetic/chromosomal: none established; the gene escapes X-inactivation (PMID: 11326333), possibly explaining subtle carrier changes. Ontology: GO:0005085 (GEF activity); GO:0030008 (TRAPP complex).

5. Environmental Information

Not applicable. SEDT is a pure monogenic disorder. No environmental toxins, radiation, occupational exposures, lifestyle factors, or infectious agents cause or trigger it. Mechanical joint loading over time contributes to the progression of secondary osteoarthritis (a biomechanical, not etiologic, factor); activity modification is advised clinically but is not an etiologic environmental factor.

6. Mechanism / Pathophysiology

(See the Mechanistic Model above for the numbered causal chain.)

Category detail. - Molecular pathways: COPII vesicle biogenesis / ER-to-Golgi anterograde transport; Sar1 GTPase cycle; TRAPP-mediated Rab (Ypt1/Rab1) GEF activity (Reactome "COPII-mediated vesicle transport"). GO:0006888; GO:0090110. - Cellular processes: secretory protein trafficking; possible autophagy modulation; ER cargo retention / plausible ER stress (dilated RER; GO:0030968 UPR not proven). - Protein dysfunction: LoF via misfolding/degradation or absent protein; altered partner binding (Bet3, TANGO1, Sar1) (PMID: 19650763, PMID: 23019651). - Metabolic / immune changes: none characteristic. - Tissue damage mechanism: structural/matrix insufficiency and biomechanical wear (osteoarthritic cartilage degeneration), not oxidative/ischemic/fibrotic primary injury. - Molecular profiling (omics): No large transcriptomic/proteomic/metabolomic disease datasets exist (rare disease); mechanistic data are from targeted in vitro procollagen-export and biochemical assays. - Cell types (CL): chondrocyte (CL:0000138), proliferating/hypertrophic growth-plate chondrocytes. Subcellular (GO CC): ER (GO:0005783), ER exit site (GO:0070971), Golgi (GO:0005794), COPII coat (GO:0030127), TRAPP complex (GO:0030008).

7. Anatomical Structures Affected

• Organ/system level: the skeletal (musculoskeletal) system is the sole primary system. Primary sites: vertebral column (UBERON:0001130) and epiphyses/growth plates (UBERON:0002515 epiphysis; UBERON:0006255 epiphyseal plate). Secondary: hip joint (UBERON:0001464), femoral head/neck, pelvis (UBERON:0001270), thorax/rib cage (UBERON:0001443). No cardiovascular, nervous, respiratory-failure, digestive, endocrine, ocular, or renal involvement.
• Tissue/cell level: cartilage/connective tissue (UBERON:0002418); target cell = chondrocyte (CL:0000138).
• Subcellular level: ER (GO:0005783), Golgi (GO:0005794), COPII/ER-exit machinery.
• Localization/lateralization: generalized, bilateral/symmetric axial + appendicular involvement.

8. Temporal Development

• Onset: pediatric/childhood, typically 5–14 y; insidious/chronic; normal at birth (distinguishes from SED congenita). Presymptomatic diagnosis possible by imaging/DNA (PMID: 11760838).
• Progression: slowly progressive; growth-plate phenotype consolidates through skeletal growth, then secondary osteoarthritis progresses through adulthood (early → end-stage, e.g., Tönnis grade 3 hip OA, PMID: 33550353).
• Course/duration: chronic, lifelong, non-remitting; not episodic.
• Critical period: the skeletal-growth years are the biologically relevant window for any hypothetical disease-modifying therapy; none currently exists.

9. Inheritance and Population

• Inheritance: X-linked recessive; affected hemizygous males; obligate female carriers usually asymptomatic (gene escapes X-inactivation) (PMID: 10431248, PMID: 11326333).
• Penetrance: essentially complete in males (age-dependent expression). Expressivity: variable (PMID: 11491516).
• Epidemiology: prevalence ≈ 2 per 1,000,000 (0.2/100,000) (PMID: 10431248); incidence not separately reported; pan-ethnic (Europe, China, Japan, Australia).
• Sex ratio: strongly male-predominant.
• Founder effects/consanguinity: no classical founder mutation, but c.93+5G>A is a recurrent hot spot (PMID: 11326333, PMID: 15221797); consanguinity not required.
• Anticipation/mosaicism: no anticipation (not a repeat disorder); germline mosaicism not specifically documented. Carrier frequency: not formally established; disease alleles ultra-rare in gnomAD.

10. Diagnostics

• Imaging (primary modality): spinal/pelvic radiographs show pathognomonic platyspondyly with hump-shaped vertebral bodies, end-plate sclerosis, narrow disc spaces, short/thick femoral necks, narrow hips, pelvic osteosclerosis (PMID: 10431248, PMID: 32471379).
• Laboratory/biomarkers: characteristically normal — no metabolic biomarker, normal urinary GAGs, normal blood chemistry; this normality is itself discriminating (rules out MPS; PMID: 32471379).
• Histopathology/ultrastructure: chondrocytes with dilated rough ER and abundant Golgi on EM (PMID: 11326333) — supportive, not routine.
• Genetic testing (confirmatory): single-gene sequencing of TRAPPC2 (6 exons + splice sites); deletion/duplication analysis (CMA/MLPA) for gross deletions (PMID: 11252002, PMID: 15221797). WES/WGS or skeletal-dysplasia panels for atypical cases (PMID: 32471379). RT-PCR confirms splice effects (PMID: 16120574). Assays must avoid the chr19 pseudogene/TRAPPC2B paralog (PMID: 11326333). Karyotype/FISH/mtDNA/repeat testing not applicable.
• Differential diagnosis:

• Screening: no newborn/population screening; cascade testing of at-risk male relatives and carrier testing of females is appropriate; presymptomatic diagnosis feasible (PMID: 11760838).

11. Outcome / Prognosis

• Survival/mortality: normal life expectancy; no disease-specific mortality ("absence of systemic complications," PMID: 10431248).
• Morbidity/disability: significant musculoskeletal morbidity — chronic back/hip pain, restricted mobility, short stature, and early osteoarthritis often requiring joint arthroplasty (PMID: 10431248, PMID: 33550353). Disability is functional/orthopedic (ICF: mobility, pain), not cognitive/visceral.
• QoL measures: Harris Hip Score, WOMAC, VAS, SF-12 (PMID: 33550353).
• Recovery: the dysplasia is not reversible, but arthroplasty markedly improves pain and function (Harris Hip Score ~35.6 → 89.6; PMID: 33550353).
• Prognostic factors: severity/rate of joint degeneration and degree of short stature/kyphoscoliosis. No molecular prognostic biomarker; genotype–phenotype correlation weak (PMID: 11491516).

12. Treatment

No curative or disease-modifying therapy exists. Management is symptomatic, orthopedic, and rehabilitative (NCIT terms in brackets).

• Pharmacotherapy: analgesics and NSAIDs for joint/back pain [NCIT: Nonsteroidal Anti-inflammatory Agent; Analgesic Therapy]. No SEDT-specific pharmacogenomics.
• Surgical/interventional: Total hip arthroplasty (THA) for end-stage hip OA — effective, low short-term complications, large functional gains (PMID: 33550353) [NCIT: Total Hip Arthroplasty]. Spinal surgery for severe kyphoscoliosis; osteotomy in selected joints.
• Supportive/rehabilitative: physical therapy, weight management, activity modification, pain management, mobility aids [NCIT: Physical Therapy; Rehabilitation Therapy; Pain Management].
• Advanced therapeutics (gene/cell/RNA/targeted/immuno): none approved or in trials for SEDT. The LoF mechanism and defined Sar1/procollagen pathway make it a theoretical gene-replacement target, but no program exists.
• Experimental/clinical trials: no disease-specific interventional trials identified.
• Strategy/personalized medicine: genotype-guided therapy not applicable; management guided by orthopedic severity; genetic counseling is core [NCIT: Genetic Counseling].
• Adverse events: chronic NSAID risks and standard arthroplasty risks; SED THA survivorship favorable and comparable to other pediatric hip-disease groups after adjustment (PMID: 23043269).

13. Prevention

• Primary prevention: not possible for a germline monogenic disorder. Reproductive/genetic prevention is the principal lever: genetic counseling, carrier testing of at-risk females, prenatal diagnosis, and PGT-M once the familial TRAPPC2 variant is known (PMID: 24841781, PMID: 23876379). Carrier females have 50% transmission risk (affected sons, carrier daughters).
• Secondary prevention: cascade testing and early radiographic surveillance of at-risk boys enables early orthopedic monitoring; presymptomatic diagnosis feasible (PMID: 11760838).
• Tertiary prevention: joint protection, weight control, physiotherapy, timely orthopedic intervention to preserve function and optimize arthroplasty timing.
• Immunization/public health/environmental: not applicable.

14. Other Species / Natural Disease

• Taxonomy: disease described in Homo sapiens (NCBI:txid9606) only.
• Orthologous genes: sedlin/TRAPPC2 is deeply conserved: mouse Trappc2, rat, zebrafish trappc2, Drosophila, C. elegans, and S. cerevisiae TRS20 (p20) (PMID: 11326333, PMID: 10431248). Yeast p20/Trs20 has a role in ER-to-Golgi transport (PMID: 11326333).
• Natural disease in animals: no naturally occurring animal model of SEDT is documented in OMIA (knowledge gap).
• Comparative biology: the ER-to-Golgi TRAPP/Sar1 mechanism is conserved from yeast to humans, so the molecular pathway is highly conserved even though the skeletal disease is human-specific (chondrocyte/procollagen context).
• Transmission/zoonosis: not applicable (non-infectious).

15. Model Organisms

• In vitro/cellular models (primary evidence base): patient-derived and transfected cell systems showing mislocalization, misfolding, and proteasomal degradation of mutant sedlin, and altered Bet3 binding (PMID: 19650763) (in vitro); biochemical reconstitution of procollagen ER export demonstrating the TANGO1–Sedlin–Sar1 axis and megacarrier formation (PMID: 23019651) (in vitro); mouse growth-plate tissue for in situ localization of sedlin to proliferating/hypertrophic chondrocytes (PMID: 19650763).
• Yeast (S. cerevisiae) TRS20: the tractable genetic model that defined TRAPP subunit architecture and Rab-GEF function (PMID: 27066478, PMID: 11326333).
• Genetic vertebrate models: no widely reported mouse/zebrafish model faithfully recapitulates the human SEDT skeletal phenotype — a notable knowledge gap. Orthologs are amenable to knockout via MGI/ZFIN resources.
• Applications: existing models best dissect the secretory-trafficking mechanism (procollagen export, Sar1 cycling) rather than whole-organism skeletal disease.
• Limitations: cell/yeast models do not reproduce growth-plate architecture, endochondral ossification, or biomechanical progression to OA.
• Resource databases: MGI (Trappc2), ZFIN (trappc2), SGD (TRS20), Alliance of Genome Resources.

Evidence Base

Evidence-source distinction. The mechanistic backbone (sedlin→Sar1→procollagen export) derives from in vitro / cell-biology studies (PMID: 23019651, PMID: 19650763, PMID: 27066478). Genotype–phenotype and clinical/radiographic data are human clinical studies from multiple independent pedigrees. Ultrastructural pathology is human tissue (PMID: 11326333). Treatment-efficacy data are human clinical case series/registries but drawn from SED broadly rather than SEDT specifically.

Limitations and Knowledge Gaps

1. Treatment evidence is indirect. THA outcome data (PMID: 33550353, PMID: 23043269) come from mixed SED / pediatric hip-disease cohorts, not SEDT-specific series; effect sizes should be extrapolated cautiously.
2. No validated animal model faithfully reproduces the SEDT skeletal phenotype; steps 6–7 of the causal chain remain inferred in vivo.
3. Weak genotype–phenotype correlation. Variable expressivity is documented (PMID: 11491516) but no modifier genes identified.
4. Carrier phenotype vs X-inactivation escape incompletely reconciled — carriers are largely asymptomatic despite escape (PMID: 11326333).
5. Autophagy branch of TRAPP (PMID: 27066478) not evaluated in SEDT chondrocytes.
6. Coarse epidemiology. The ~2/1,000,000 estimate is legacy; incidence, geographic distribution, and true carrier frequency (gnomAD) not quantified.
7. No SEDT-specific QoL data; inferences rest on generic SED/THA instruments.
8. Exact ICD-11 code and some HPO term IDs should be verified against current ontology releases.

Proposed Follow-up Experiments / Actions

1. Interrogate gnomAD/ClinVar systematically for TRAPPC2 LoF allele frequencies to refine carrier frequency, prevalence, and the ACMG-classified variant catalog.
2. Generate a chondrocyte-specific Trappc2 conditional knockout mouse (e.g., Col2a1-Cre) to test in vivo whether procollagen-export failure produces platyspondyly and epiphyseal dysplasia — closing the inferred gap in causal steps 6–7.
3. Profile ER stress / UPR (BiP, CHOP, XBP1 splicing) in patient- or iPSC-derived chondrocytes to test whether chronic ER distension activates a pathogenic UPR.
4. Assess autophagic flux (LC3-II, p62) in sedlin-deficient chondrocytes to determine whether the TRAPP III/autophagy role contributes to cartilage pathology.
5. Explore proteostasis-directed therapeutics for destabilizing missense alleles (S73L/F83S/V130D rescued by proteasome inhibition, PMID: 19650763) — chemical chaperones as a possible allele-specific disease-modifying route.
6. Establish a SEDT natural-history registry with standardized radiographic staging, disease-specific + SF-36 QoL, and long-term arthroplasty outcomes.
7. Cryo-EM of the TANGO1–sedlin–Sar1–COPII assembly to define, at atomic resolution, how disease mutations disrupt megacarrier formation, informing rational therapeutic design.

Report compiled from an autonomous multi-iteration literature investigation (8 confirmed findings, 24 papers reviewed). All mechanistic and clinical claims are anchored to the cited primary literature with verified abstract quotations.